FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

27 NEW ARTICLES FROM TODAY'S NEWS ARE BELOW:

 Treatment trials in progressive MS-current challenges and future directions.

 Sex and Multiple Sclerosis

Update on therapeutic options for multiple sclerosis.


A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality.

Neuronal degeneration is observed in multiple regions outside the hippocampus after lithium pilocarpine-induced status epilepticus in the immature rat.

Medical Procedures May Be Useless, or Worse- New York Times

Cognitive reserve in multiple sclerosis

 Wild goalie Josh Harding learns to live with MS, launches charity

Perrigo To Buy Elan For $8.6B, Seeks Tax Savings-Tysabri, a joint venture with the Massachusetts-based drugmaker Biogen Idec, ... Elan sold much of its ownership share of Tysabri to Biogen Idec in February for ...

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction

1H-Magnetic Resonance Spectroscopy in diffuse and focal cervical cord lesions in Multiple Sclerosis.

Anti-neurofascin antibody in patients with combined central and peripheral demyelination.

Association between multiple sclerosis risk-associated SNPs and relapse and disability - a prospective cohort study.

The clinico-radiological paradox in multiple sclerosis: novel implications of lesion size.

Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.

The Potential for New Therapeutic Approaches: Global Research ...
Wall Street Journal-The focus of the program is the interaction between laquinimod, a neuroprotective agent currently being investigated in multiple sclerosis, and various molecular ...

Tisch MS Researchers Announce Breakthrough in Disease Monitoring

Actress tells of revolutionary MS treatment

Multiple sclerosis awareness race scheduled Sept. 6

BASF in Wyandotte Raises $15K for Michigan Multiple Sclerosis

Ride to fight MS


MicroRNA regulate immune pathways in T-cells in multiple sclerosis ...

Los Angeles Medical Marijuana Provider CannaMed Now Providing ...


Mitochondrial dysfunction and neurodegeneration in multiple sclerosis.

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given.

Labels:



Go to Newer News Go to Older News